Metabolic Effects of Treatment in Patients With Recently Diagnosed Type 2 Diabetes

This study has been completed.
Sponsor:
Collaborator:
University of Athens
Information provided by (Responsible Party):
Nikolaos Kadoglou, Aristotle University Of Thessaloniki
ClinicalTrials.gov Identifier:
NCT00373178
First received: September 6, 2006
Last updated: November 1, 2012
Last verified: November 2012
  Purpose

The aim of the present study is to investigate the influence of several anti-diabetic regimens (metformin,glitazone,sulfonylurea,glinidine) and diet on metabolic parameters in patients with recently diagnosed type 2 diabetes.


Condition Intervention Phase
Type 2 Diabetes Mellitus
Drug: rosiglitazone
Drug: metformin
Drug: Anti-diabetic medications
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Metabolic Effects of Treatment in Patients With Recently Diagnosed Type 2 Diabetes

Resource links provided by NLM:


Further study details as provided by Aristotle University Of Thessaloniki:

Primary Outcome Measures:
  • Novel cardiovascular risk factors modification [ Time Frame: 2 years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Lipid and glucose regulation [ Time Frame: 2 years ] [ Designated as safety issue: No ]

Enrollment: 100
Study Start Date: January 2005
Study Completion Date: June 2008
Primary Completion Date: January 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Metformin,lifestyle counselling Drug: rosiglitazone Drug: metformin Drug: Anti-diabetic medications

  Eligibility

Ages Eligible for Study:   40 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Recently diagnosed type 2 diabetes
  • No previous anti-diabetic medications

Exclusion Criteria:

  • Heart failure
  • Renal disease
  • Liver disease
  • Life-threatening diseases
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00373178

Locations
Greece
AHEPA University Hospital of Thessaloniki
Thessaloniki, Greece
Aristotle University of Thessaloniki
Thessaloniki, Greece
Sponsors and Collaborators
Aristotle University Of Thessaloniki
University of Athens
Investigators
Study Chair: Miltiadis Alevizos, PhD University Hospital AHEPA,Thessaloniki,Greece
  More Information

No publications provided by Aristotle University Of Thessaloniki

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Nikolaos Kadoglou, MD,PhD, Aristotle University Of Thessaloniki
ClinicalTrials.gov Identifier: NCT00373178     History of Changes
Other Study ID Numbers: 020401975
Study First Received: September 6, 2006
Last Updated: November 1, 2012
Health Authority: Greece: National Organization of Medicines

Keywords provided by Aristotle University Of Thessaloniki:
rosiglitazone
metformin

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Endocrine System Diseases
Glucose Metabolism Disorders
Metabolic Diseases
Hypoglycemic Agents
Metformin
Rosiglitazone
Pharmacologic Actions
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on October 20, 2014